Sander Van Deventer 

Biography

  Dr. Sander van Deventer, M.D., Ph.D., is a Managing Partner at Forbion Capital Partners. Dr. van Deventer has been a Venture Partner at ABN AMRO Capital Benelux since 2004. He is a Co-Founder of uniQure N.V. and has been its Chief Scientific Officer and General Manager of Amsterdam since August 7, 2017. He served as Advisor of uniQure N.V. He has been a Scientific Advisor to Amsterdam Molecular Therapeutics (AMT) Holding N.V., since October 2009. He is a part-time Chief Scientific Officer at Amsterdam Molecular Therapeutics (AMT) Holdings N.V. which he co-founded in 1998. He serves as a Consultant to major pharma and to a significant number of large biotech companies. Dr. van Deventer has extensive experience in translational research with particular emphasis on drug development and significant regulatory experience with the European Agency for the Evaluation of Medicinal Products (EMEA) and Food and Drug Administration (FDA). He has significant experience in the medical and life sciences field. Dr. van Deventer is a Professor of Experimental Medicine at the University of Amsterdam Medical School. Dr. van Deventer is a Professor of Translational Gastroenterology Leiden University Medical Center. Dr. van Deventer was a General Partner at Forbion Capital Partners. He served as Interim Chief Executive Officer at uniQure N.V. from February 2009 to October 2009. He served as a Venture Partner of AAC Capital Partners (ABN AMRO Capital) in 2004. He served as an Interim Chief Executive Officer at Dezima Pharma B.V. Dr. van Deventer has held a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He was Interim Chief Executive Officer of Amsterdam Molecular Therapeutics (AMT) Holdings N.V. from February 1, 2009 to October 5, 2009 and served as its Member of Management Board from July 5, 2005 to October 2009 and Member of its Supervisory Board. He used this knowledge to first administer an anti-TNF monoclonal antibody to patients with Crohn’s disease. Following graduation, he worked as a Scientist in the Laboratory for Medical Biochemistry, Rockefeller University. Since 1995, Dr. van Deventer served as Director of the Laboratory for Experimental Internal Medicine at the Academic Medical Center, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. Dr. van Deventer has advised the Dutch government on several projects, including the national colorectal screening program and the translational gene therapy program. He serves as Chairman and Member of the Scientific Advisory Board at Amsterdam Molecular Therapeutics (AMT) Holdings N.V. Dr. van Deventer has been a Director at Argos Therapeutics, Inc. since 2001. He has been a Director of enGene, Inc. since January 26, 2015. Dr. van Deventer serves as a Director of Replimune Ltd, gIcare Pharma Inc., Cardoz AB, Merix bioscience and en Hookipa. He serves as a Member of Scientific Advisory Board of NovImmune SA and AM-Pharma B.V. He has been Member of Scientific Advisory Board of uniQure N.V.BV since April 2012. From 2001 to 2004, Dr. van Deventer was the Chairman of the Department of Gastroenterology and Hepatology at the Academic Medical Center. He served as a Member of Clinical Advisory Board at ChemoCentryx, Inc. He served as the Chairman of the Anton Meelmeijer Center for Genomics and Proteomics at the University of Amsterdam Medical School. Dr. van Deventer served as Vice Chairman and Director of Borean Pharma ApS. He held positions on the Advisory Boards of the FDA and the EMEA. He served as a Director of uniQure N.V. since 2010 until September 14, 2017. He served as a Member of Supervisory Board at uniQure N.V. since April 2012 until June 15, 2016. He is the author of more than 80 book chapters and 500 peer reviewed scientific papers. Dr. van Deventer is the author of numerous articles and book chapters on inflammatory and infectious diseases and cancer and is the principal investigator for several clinical trials using novel small molecules, peptides, antisense RNA, antibodies and cell therapies. He has organized several large international scientific conferences and under his supervision more than 40 students have completed their Ph.D. thesis. He is trained and Board certified in Internal Medicine and Gastroenterology. Dr. van Deventer completed a Ph.D. thesis on the Mechanisms of Endotoxin-induced Inflammation and on the biological activities of bacterial lipopolysaccharides in humans and received his Medical degree and Ph.D. in biological activities from the University of Amsterdam.  

Research Interest

 medicine